<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094847</url>
  </required_header>
  <id_info>
    <org_study_id>DW_J1252001P</org_study_id>
    <nct_id>NCT01094847</nct_id>
  </id_info>
  <brief_title>Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine</brief_title>
  <official_title>Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and explore bioavailability of mosapride, the main
      component of DWJ1252(Test drug) and mosapride medicine(Reference drug).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of Mosapride</measure>
    <time_frame>48hr after 1st administration</time_frame>
    <description>AUC(0-last), Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of mosapride, M-1</measure>
    <time_frame>48hr after 1st administration</time_frame>
    <description>AUCoo, tmax, t 1/2, CL/F, Vd/F of Mosapride
AUC(0-last), AUCoo, Cmax, tmax, t 1/2 of M-1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1252 given by oral administration under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DWJ1252 given by oral administration, 30 minutes after a meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>mosapride by oral administration 30 minutes before meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1252</intervention_name>
    <description>tablet(oral) administration following the schedule of each arm</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a healthy adult male within the range of 20 to 50 years old at the time of screening

          -  with weight of more than 55kg, in the range of IBW 20%: IBW(kg)={height(cm)-100}*0.9

          -  who understood completely about this study after the detailed explanation is given,
             decided to volunteer and gave written informed consent to participate in study in
             compliance with the requirement of the entire protocol.

        Exclusion Criteria:

          -  one with clinically significant disease in liver, kidney, nerve system, respiratory
             system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental
             disease or with medical history

          -  one with gastrointestinal disease or with gastrointestinal surgical history which can
             affect the absorption of the investigational drug.

          -  one with genetic disease like galactose intolerance, Lapp lactase deficiency, or
             glucose-galactose malabsorption

          -  one who is allergic or has clinically significant allergic history to the component of
             the investigational drug (mosaprisde), and any component from same family, or to other
             drugs(Aspirin, antibiotics, etc)

          -  one who shows different rhythm than sinus rhythm in screening, like QTc &gt;450ms on
             electrocardiogram, PR interval&gt;200msec or QRS interval 120&gt;msec

          -  one who shows the following result in clinical laboratory test: AST,ALT&gt;1.25 times of
             the upper limit of normal range

          -  one who shows vital signs with the number of systolic blood pressure of 160 mmHg or
             100 mmHg, and the number of diastolic blood pressure of 95mmHg or 60mmHg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital IRB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Somin Bae</name_title>
    <organization>Daewoong Pharmaceutical Co. LTD</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

